What is HC Wainwright’s Estimate for NBIX Q4 Earnings?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at HC Wainwright dropped their Q4 2025 EPS estimates for Neurocrine Biosciences in a research report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of $1.06 for the quarter, down from their previous forecast of $1.20. HC Wainwright currently has a “Buy” rating and a $185.00 price target on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences’ FY2026 earnings at $4.43 EPS, FY2027 earnings at $7.33 EPS and FY2029 earnings at $14.69 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Other equities research analysts have also issued reports about the stock. Guggenheim decreased their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Royal Bank of Canada cut their price objective on Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a research report on Friday, February 7th. Barclays increased their target price on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, December 23rd. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 18th. Finally, Bank of America dropped their price objective on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $166.90.

Neurocrine Biosciences Stock Performance

NBIX opened at $115.90 on Monday. The company has a market cap of $11.56 billion, a price-to-earnings ratio of 35.23, a PEG ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a one year low of $110.95 and a one year high of $157.98. The business’s fifty day moving average is $136.35 and its two-hundred day moving average is $129.11.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Caprock Group LLC acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth approximately $236,000. Plato Investment Management Ltd grew its holdings in Neurocrine Biosciences by 2,481.9% during the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after acquiring an additional 10,548 shares in the last quarter. Swiss National Bank increased its position in shares of Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after purchasing an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp acquired a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $3,236,000. Finally, KBC Group NV lifted its position in shares of Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after purchasing an additional 8,332 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock in a transaction on Monday, January 27th. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the sale, the director now owns 514,596 shares of the company’s stock, valued at $76,911,518.16. The trade was a 22.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Matt Abernethy sold 1,283 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.87, for a total transaction of $196,132.21. Following the completion of the transaction, the chief financial officer now directly owns 32,681 shares of the company’s stock, valued at approximately $4,995,944.47. The trade was a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 236,600 shares of company stock worth $34,348,261 over the last 90 days. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences announced that its Board of Directors has authorized a stock buyback plan on Friday, February 21st that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.